Viking Therapeutics: Stock at $37.44 USD – Analysts See Price Target of $93.60 USD

Viking Therapeutics Inc. (VKTX) closed at $37.44 USD on July 3, 2026, remaining virtually unchanged compared to the previous day ($37.44 USD). Trading volume was 20,069 shares, while the daily range fluctuated between $36.69 USD and $38.87 USD.

Analyst Consensus Shows Strong Upside Potential

Financial analyst valuations are predominantly positive. Of 24 total assessments tracked (as of July 5, 2026), 22 analysts assigned a "Buy" rating and one a "Strong Buy" rating. Only one analyst recommends the stock with a "Hold" rating, while no sell recommendations ("Sell" or "Strong Sell") are present.

The average analyst price target is $93.60 USD, with a median target of $95.00 USD. The range of price targets spans from $83.00 USD to $101.00 USD. Relative to the closing price on July 3, 2026, the median price target represents potential upside of approximately 150 percent.

Technical Indicators Point to Uptrend

The Relative Strength Index (RSI), a momentum indicator that measures overbought or oversold market conditions, stood at 64.84 on July 2, 2026. Values between 30 and 70 are considered neutral, while values above 70 suggest overheating. The current RSI thus lies in the positive range without signaling overheating conditions.

In preceding trading days between late June and early July, the RSI moved multiple times above the 70 mark, reaching a local high of 75.36 on June 29. Since June 12, when the RSI stood at 42.25, the indicator has shown a clear uptrend.

Business Model Focused on Metabolic Diseases

Viking Therapeutics is a clinical-stage biopharmaceutical company specializing in novel therapies for metabolic and endocrine disorders. The company focuses on developing medicines tailored to specific receptors and tissues.

The lead candidate in the product portfolio is VK2809, an orally administered, tissue- and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This drug candidate is currently in Phase IIb studies for treatment of non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients, as well as non-alcoholic fatty liver disease (NAFLD).

Additional drug candidates in the pipeline include VK5211, a non-steroidal selective androgen receptor modulator (SARM) for patients following non-elective hip fractures, and VK0612 for Type 2 diabetes, which is expected to enter Phase IIb studies.

Trading Activity and Market Environment

The trading volume of 20,069 shares on July 3, 2026, is below the average for comparable trading days. For comparison: in the preceding week, daily volumes sometimes reached six figures. The moderate activity suggests a quiet trading environment, typical for summer months and near holidays.

The stock trades in US dollars. For investors in the DACH region settling in Swiss francs or euros, currency risks arise that should be factored into valuations. The current USD/CHF and USD/EUR exchange rates influence actual returns in the home currency.

Risks and Opportunities in Biotech Investments

Investments in clinical-stage biopharmaceutical companies carry inherent risks. Success depends significantly on the outcome of ongoing and future clinical trials. Positive study results can lead to substantial share price gains, while setbacks in development or regulatory hurdles can trigger significant losses.

The broad analyst support and considerable upside potential to the average price target of $93.60 USD reflect expectations for the product pipeline. The focus on metabolic diseases such as NASH and NAFLD addresses a growing market, as these conditions are increasing globally and currently have limited therapeutic options.

The technical indicators support the positive assessment, with the RSI indicating intact upward momentum while the stock does not appear overbought in the short term. Price development since mid-June shows stabilization and recovery following a prior weakness phase.